Professor Martin Metz joins Professor Marcus Maurer to answer an audience proposed question focusing on what will guide physicians in the recommendations for individual patients to identify the most beneficial treatment option to treat chronic spontaneous and inducible urticaria. Both experts delve into the current treatment options available, and exciting treatments that are currently in clinical trials.
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
Utilise the following external links to access additional resources relating to the topics discussed in this episode: Dupilumab in CSU, Remibrutinib in CSU, Bruton’s tyrosine kinase inhibition—An emerging therapeutic strategy in immune-mediated dermatological conditions, An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria, Barzolvolimab in mast cell depletion, Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances, Chronic urticaria and the pathogenic role of mast cells and Urticaria (an overview).
Read more news regarding urticaria
News,webinar4U
May 8, 20247th Patient Education UCARE4U Webinar on SWELLING AND ITCHES CLICK HERE TO REGISTER Date: May 28 Time: 6 pm CET Topics and Faculty Introduction and Moderation Dr. Aiste Ramanauskaite Charité [...]
News,webinar
May 2, 2024DON'T FORGET TO REGISTER NOW UCARE LevelUp Webinar: ACUTE URTICARIA – CURRENT PERSPECTIVE AND WHAT KEY POINTS TO CONSIDER This webinar focuses on the most frequent presentation of urticaria: acute [...]
Journal Club,News
April 22, 2024Join us on Thursday, May 2 from 12.00 to 12.45 pm CET, for the UCARE LevelUP Journal Club! Zhuoran Li (IFA Berlin) will speak about “DOCK2 regulates MRGPRX2/B2-mediated mast cell degranulation and drug-induced anaphylaxis” [...]